Equities: Cautious start anticipated after US-Iran tensions – Danske Bank
Equity Markets Set for Sharp Decline Amid Rising Oil Prices
Analysts from Danske Research anticipate that stock markets will open over 1% lower, following significant losses in Asia after unsuccessful US-Iran negotiations led to a surge in Brent crude prices. The bank highlights that European indices, which outperformed on Friday, are likely to experience a downward adjustment today, even though last week saw strong investor interest in cyclical stocks and semiconductors compared to defensive sectors.
Futures Indicate Weak Start
Brent crude oil jumped above $100 per barrel on Monday morning, as talks between the US and Iran over the weekend failed to yield an agreement.
Stock futures are signaling a drop of more than 1% at the open, reflecting the widespread sell-off seen across Asian markets following the breakdown in US-Iran discussions.
While US markets had already ended lower on Friday—with the S&P 500 slipping 0.1% and high-yield credit down 0.4% despite positive inflation data—European indices performed better. The Stoxx 600 gained 0.4% and the OMX Nordic climbed 1.3%. This divergence suggests that European markets may see a sharper negative reaction today as they realign with global trends.
Notably, the technology sector stood out as one of the strongest performers in the US on Friday, even as software stocks continued to decline. The resilience of semiconductor shares could offset some of this weakness, which aligns with the research team's outlook.
Materials and real estate sectors also posted gains, whereas defensive industries such as health care and consumer staples faced declines. This pattern indicates that risk-taking remained prevalent among investors throughout the previous week, despite the negative market close.
As a result, equities and equity futures are trading in negative territory, while the US dollar has strengthened slightly.
(This report was produced with the assistance of artificial intelligence and reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million
RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.
Ledger CTO urges crypto holders to update iPhones after DarkSword exploit revealed
Crypto ICOs Left in Limbo After CLARITY Act Fails in Senate
